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Background: Exercise training is recommended for non-cystic fibrosis (CF) bronchiectasis, but the long-term effects
are unclear. This randomised controlled trial aimed to determine the effects of exercise training and review of
airway clearance therapy (ACT) on exercise capacity, health related quality of life (HRQOL) and the incidence of
acute exacerbations in people with non-CF bronchiectasis.
Methods: Participants were randomly allocated to 8 weeks of supervised exercise training and review of ACT, or
control. Primary outcomes of exercise capacity and HRQOL (Chronic respiratory disease questionnaire) and secondary
outcomes of cough-related QOL (Leicester cough questionnaire) and psychological symptoms (Hospital anxiety and
depression scale) were measured at baseline, following completion of the intervention period and at 6 and 12 months
follow up. Secondary outcomes of the exacerbation rate and time to first exacerbation were analysed over 12 months.
Results: Eighty-five participants (mean FEV1 74% predicted; median Modified Medical Research Council Dyspnoea
grade of 1 (IQR [1–3]) were included. Exercise training increased the incremental shuttle walk distance (mean difference
to control 62 m, 95% CI 24 to 101 m) and the 6-minute walking distance (mean difference to control 41 m, 95% CI
19 to 63 m), but these improvements were not sustained at 6 or 12 months. Exercise training reduced dyspnoea
(p = 0.009) and fatigue (p = 0.01) but did not impact on cough-related QOL or mood. Exercise training reduced
the frequency of acute exacerbations (median 1[IQR 1–3]) compared to the control group (2[1–3]) over 12 months
follow up (p = 0.012), with a longer time to first exacerbation with exercise training of 8 months (95% CI 7 to 9 months)
compared to the control group (6 months [95% CI 5 to 7 months], p = 0.047).
Conclusions: Exercise training in bronchiectasis is associated with short term improvement in exercise capacity,
dyspnoea and fatigue and fewer exacerbations over 12 months.
Trial registry: ClinicalTrials.gov (NCT00885521).
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Bronchiectasis unrelated to cystic fibrosis (non-CF bron-
chiectasis) is a chronic respiratory condition characterised
by bronchial dilatation secondary to airway inflammation,
infection and dysfunction of mucociliary clearance [1].
Common features include persistent cough with chronic
sputum production, dyspnoea and fatigue [2,3]. This* Correspondence: Annemarie.Lee@alfred.org.au
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unless otherwise stated.clinical profile is associated with increased anxiety and
depression, reduced health-related quality of life (HRQOL)
and impaired exercise tolerance [3,4]. Patients with non-CF
bronchiectasis frequently experience acute exacerbations
[5], which are an independent predictor of progressive
decline in respiratory function and a poorer prognosis
[6,7]. While the global prevalence of non-CF bronchiectasis
is unknown, it is associated with rising hospitalisation rates
amongst the older population [8-10]. This growing health-
care utilisation and economic burden [11,12] emphasises. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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approaches.
Current guidelines for the treatment of non-CF bronchi-
ectasis recommend pulmonary rehabilitation, with the aim
of improving exercise tolerance and HRQOL [13]. Pulmon-
ary rehabilitation often incorporates self-management strat-
egies to promote treatment adherence and this approach
has been advocated for bronchiectasis [14]. There is limited
evidence of the effects of pulmonary rehabilitation in
non-CF bronchiectasis, with two retrospective studies
demonstrating similar benefits in exercise capacity and
HRQOL as those observed in patients with chronic
obstructive pulmonary disease (COPD) [15,16]. Two
prospective studies showed short-term improvements
in exercise capacity and HRQOL with a combination of
endurance, strength training and inspiratory muscle
training [17] or regular airway clearance therapy (ACT)
[18]. These studies incorporated formal education as
part of the clinical approach and had a follow up period
of three months; it is not clear if benefits persist in the
longer term.
Health benefits are also assessed through quality-
adjusted life years (QALYs), which quantify the benefit
gained from an intervention by measuring the change in
HRQOL over time. In COPD, pulmonary rehabilitation
(exercise training and education) has been associated with
fewer acute exacerbations and improved QALYs [19].
Whether similar effects are achieved in bronchiectasis
is unknown.
Therefore, the aims of this study were to 1) determine
the short and long-term effects of exercise training and
review of ACT on exercise capacity and dimensions of
HRQOL and 2) evaluate the effect of this intervention




A multi-site, randomised, single blinded, controlled trial
was conducted at three tertiary teaching hospitals, the
Alfred and Austin Hospitals (Victoria) and Sir Charles
Gairdner Hospital (Western Australia), Australia. Adults
aged over 18 years with non-CF bronchiectasis, confirmed
on high resolution computed tomography (HRCT), were
invited to participate. The detailed methodology of this
study has been published previously [20].
Patients were eligible to participate if they were ambu-
lant and reported dyspnoea on exertion (Modified Medical
Research Council (MMRC) Dyspnoea grade ≥ 1) [21],
clinically stable and self-reported at least two exacerba-
tions requiring antibiotics per year within the previous
two years. Exclusion criteria were other concurrent
respiratory diseases, including COPD (smoking history
of greater than 10 pack years and evidence of emphysemaon HRCT) [22], interstitial lung disease (ILD) or asthma
(clinical diagnosis and reversibility > 12%) [23], comorbidi-
ties which precluded safety to undertake exercise training
or participation in pulmonary rehabilitation in the previ-
ous 12 months. The study was approved by the Human
Research Ethics Committees at all trial sites with written
informed consent obtained from all participants. The trial
was registered with ClinicalTrials.gov (NCT00885521).
After stratification for sputum quantity (small volume:
≤one tablespoon per day, large volume: > one tablespoon
per day), which was based on classifications previously
described [2] and is associated with decline in FEV1 [7],
participants were randomised to the intervention or
control group at a central location using a computer-
generated randomisation sequence, which was concealed
using sealed, opaque envelopes and prepared by an inde-
pendent individual. Baseline measurements of spirometry
were obtained and repeated immediately following the
intervention period and at follow up. Prior to randomisa-
tion, all participants received instruction and review of
their usual ACT, with instructions standardised across
sites. Any participant who had no prior instruction in
ACT was taught the active cycle of breathing technique
[24] while those with established ACT had their technique
reviewed and corrected if necessary. All participants, irre-
spective of group allocation, were encouraged to continue
with their ACT for the study duration.
Intervention
The intervention group attended a twice-weekly exercise
program for eight weeks at the institution in which they
were recruited. Exercise training consisted of an individu-
ally prescribed exercise program and included treadmill or
land based walking, with the initial intensity set to 75% of
the maximal speed achieved on the incremental shuttle
walk test (ISWT) [25,26], stationary cycling prescribed at
60% of maximal work-rate for cycling [27] and upper and
lower limb strength training using free weights and/or
body weight [25,26]. Exercises were progressed each ses-
sion according to patient symptom ratings (modified Borg
scale for dyspnoea and perceived exertion), similar to
COPD training principles [25,26]. Attendance of at least
12 out of 16 exercise sessions was considered completion
of the exercise intervention [28]. Following the establish-
ment of a safe exercise regimen, a home exercise program
was prescribed in week one, with the aim of achieving
three to five unsupervised sessions per week with sessions
recorded in an exercise diary. Participants were instructed
to maintain this routine during the follow up period
and were reminded via monthly telephone calls over
the follow up period. To encourage adherence to ACT,
an average rating of sputum volume using a visual
analogue scale (VAS) was recorded weekly. If necessary,
ACT was reviewed and corrected.
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training but were informed at baseline that undertaking
30 minutes of moderate intensity physical activity most
days of the week was associated with health benefits
[29]. During the eight week intervention, participants
were contacted by telephone twice-weekly, to provide
support and general advice with no discussion of exercise
or physical activity. The control group did not complete
an average sputum rating and did not have an opportunity
for their ACT to be reviewed or corrected.Outcome measures
Over two days of assessment at each time point, primary
and secondary outcomes were measured at baseline,
immediately following the intervention (nine weeks) and
at six and 12 months post intervention by an assessor
blinded to group allocation. One site did not participate in
the long term follow up due to ethical concerns relating
to denial of exercise training to the control group for
12 months. The primary outcome of maximal exercise
capacity was the incremental shuttle walk distance (ISWD),
with the ISWT performed to a standardised protocol
[30]. Two tests were completed at each assessment,
with the maximal distance of two tests recorded [30].
The self-reported version of the Chronic respiratory
disease questionnaire (CRDQ) was used to measure
HRQOL [31]. This has been previously used to assess
HRQOL in patients with bronchiectasis [15].
Secondary outcomes included functional exercise cap-
acity, measured with the 6-minute walk test (6MWT).
Two tests were completed on each assessment occasion
to a standardised protocol, with the maximal 6-minute
walk distance (6MWD) of the two tests recorded [32].
The Leicester cough questionnaire (LCQ) was applied to
measure the physical, psychological and social impact of
chronic cough [33] and the Hospital anxiety and depression
scale (HADS) measured psychological symptoms of anxiety
and depression [34].
To determine an individual’s utility of health status at a
specific point in time, the Assessment of Quality of Life
(AQOL) was applied [35]. The AQOL has five dimensions
including illness, independent living, social relationships,
physical senses and psychological well-being, with item re-
sponses based on four point ordinal scales. The AQOL
was converted into a value index using preference weights
derived from Australian population samples, which were
combined into a single score of the utility index [35]. The
highest score of 1 represents perfect health, 0 represents
death and negative values (i.e. -0.04) represent a state of
worse than death. The health state was then multiplied
by the time spent in that state (one year in this study)
to derive the QALYs gained or lost following an inter-
vention [19,35].During the eight week intervention period and over the
12 month follow up, all participants maintained a daily
diary recording changes in symptoms. This symptom
record was used to identify an exacerbation, which was
defined as the presence of ≥ four signs and symptoms
(including change in sputum amount, thickness or colour,
haemoptysis, increased cough, tiredness, shortness of
breath or fever> 38 degrees Celcius) [5] for two or
more consecutive days with and without prescription of
new antibiotics. To ensure adherence to diary completion,
participants in both groups were contacted by telephone
monthly over the follow up period. Exacerbation data
were extrapolated from diary records by an independent
assessor blinded to group allocation, which was then veri-
fied with the participant’s general practitioner or hospital
records.
Statistical analysis
For the primary outcomes, for an 80% probability of de-
tecting a difference in ISWD, a total of 36 participants
were required, based on the assumption of a difference
between groups of 55 m, with a standard deviation (SD)
of 74 m [3]. For an 80% probability of detecting a differ-
ence in HRQOL, 44 subjects were required. This was
based on the assumption that a difference between groups
is 5.4 units for the CRDQ emotional function domain,
with a SD of 6.3 units using an unstandardised scale,
according to pilot data collected on 33 patients at one
recruiting centre. For the secondary outcomes, for an 80%
probability of detecting a difference in number of exacerba-
tions, 64 participants were required, based on the assump-
tion that a difference between groups was 1.0 exacerbation,
with a SD of 1.4 exacerbations [7]. To account for 20%
attrition, a total of 85 subjects were recruited.
Data analysis was completed based on intention-to-
treat principles, in which all participants were scheduled
to attend follow up assessment, irrespective of completion
and all available data from participants attending these
assessment (Figure 1) has been included in the analysis
[36]. Missing data were replaced by the last observation
carried forward method (LOCF), with the robustness of
this analysis checked with a sensitivity analysis in which
the observed means from the exercise and control groups
were substituted for missing data in the opposite arm
[37]. The sensitivity analysis confirmed the results of
the primary endpoint and hence LOCF analyses have been
reported. Data were expressed as mean and standard
deviation (SD) or median and interquartile range (IQR).
Analysis was completed using two way analysis of vari-
ance to account for group and time interaction. Non
parametric data were compared between groups using
the Mann Whitney U test. Time to first exacerbation
was assessed via Kaplan-Meier survival analysis using
log-rank tests to compare groups. Analyses were performed
Figure 1 Flow of participants.
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version 17.0; Chicago, IL, USA) with p < 0.05 used to
denote statistical significance.
Results
Between April 2009 and February 2011, a total of 144
patients were screened (Figure 1), 36 were excluded prior
to randomisation for not meeting the inclusion criteria
and a further 23 declined to participate. The subject flow
reflected the recommendations from the Consolidated
Standards of Reporting Trials (CONSORT) statement [38].A total of 42 were randomised to the exercise training
group and 43 to the control group. All participants had
been previously prescribed ACT. For those in the interven-
tion group, no changes to ACT regimens were required by
any participant over the eight week duration and the aver-
age VAS sputum volume rating did not change over the
intervention period (p = 0.56). Adherence to exercise diary
completion during the 8 week program in the exercise
group was 29%. All control group participants reported no
change to their usual exercise patterns between baseline
assessment and at 9 weeks follow up.
Figure 2 Change in incremental shuttle walk distance (A) and
6-minute walk distance (B). Data are mean (95% CI), *p < 0.05,
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the study during the intervention phase due to an illness
unrelated to bronchiectasis. Data for this participant were
not available at nine weeks, six or 12 months. There was
one death in the control group from respiratory failure.
A total of 38 (90%) participants completed the exercise
training, with reasons for non-completion outlined in
Figure 1. Reasons for not undertaking outcome mea-
sures at the nine week assessment were respiratory illness
(n = 3), fractured thoracic spine which was unrelated to
exercise training (n = 1) or declined to attend (n = 4).
Baseline characteristics of the 85 participants are shown
in Table 1, with no difference between groups at baseline
in any measures. According to the MMRC Dyspnoea
grade, the extent of functional impairment in exercise
capacity was mild with 64 (75%) participants reporting
dyspnoea only on strenuous activity (MMRC Grade 1).
There was no change in FEV1 (p = 0.26) or FVC% pre-
dicted (p = 0.43) over the study duration in either group.
The effect of exercise training on maximal exercise
capacity is shown in Figure 2. There was a significant
interaction between group and time for ISWD (p = 0.005).
The ISWD improved in the exercise group following
training, with a mean difference (95% CI) of 62 m (24
to 101 m) compared to the control group. However, this
improvement was not sustained at either six or 12 months.





Gender: Male/Female 12/31 12/30
Age (years) 65 (12) 63 (13)
BMI (kg/m2) 24.2 (4.5) 24.7 (5.9)
FEV1% predicted 77 (18) 70 (23)
FVC% predicted 84 (18) 79 (22)
FEV1/FVC 80. (14) 82 (12)
MMRC 1.5 (0.7) 1.3 (0.5)
6MWD (m) 578 (90) 551 (90)
6MWD% predicted 84 (12) 85 (12)
ISWD (m) 474 (157) 464 (150)
ISWD% predicted 77 (22) 76 (24)
Total CRDQ score 91.0 (18.6) 88.9 (16.1)
Total LCQ score 14.5 (3.6) 15.1 (3.1)
HADS Anxiety 4.4 (3.1) 4.8 (3.4)
HADS Depression 3.5 (2.8) 3.1 (2.9)
No of exacerbations in previous 2 years 5.3 [4.8] 5.1 [4.6]
Data are mean (SD) or median [IQR] unless otherwise stated. BMI - Body mass
index; FEV1 - Forced expiratory volume in 1 second; FVC - Forced vital capacity;
MMRC – Modified Medical Research Council Dyspnoea Scale; 6MWD – 6-minute
walk distance; ISWD – Incremental shuttle walk distance; CRDQ – Chronic
Respiratory Disease Questionnaire; LCQ – Leicester Cough Questionnaire;
HADS – Hospital Anxiety and Depression scale; No – number.
exercise vs control group.significant reduction in dyspnoea (p = 0.009) and fatigue
(p =0.01) compared to the control group immediately
following training (Figure 3), but these improvements
were not sustained when assessed at six and 12 months.
There was no significant change in emotional function
or mastery.
Of the secondary outcomes, there was a significant
improvement in functional exercise tolerance following
training, with a mean change (95% CI) in 6MWD of
41 m (19 to 63 m) compared to the control group, but
this improvement was not sustained over the longer term.
There were no significant differences between groups in
any of the LCQ domains or in anxiety or depression im-
mediately following intervention or at follow up (Table 2).
The adherence rate to symptom diary completion was
82% in the exercise group and 77% for the control group.
A total of 12 participants in the exercise group and 18 in
the control group experienced at least one exacerbation
over the 12 months follow up. There was a longer median
time to first exacerbation in the exercise group of
8 months (95% CI 7 to 9 months), compared to control
group of 6 months (5 to 7 months), with log rank of
0.49 (95% CI 0.01 to 0.97), p = 0.047 (Figure 4). Exercise
training reduced the number of exacerbations over
Figure 3 Change in health-related quality of life – Chronic Respiratory Disease Questionnaire domains, Data are mean (95% CI),
*p < 0.05, exercise vs control group.
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erbations requiring antibiotics (p = 0.061). There was
no significant difference between groups in the number
of days or exacerbation days requiring antibiotics for
each exacerbation. The relative risk of exacerbation was
0.69 (95% CI 0.49 to 0.98), indicating there was less risk
of exacerbation in the exercise group compared to the
control group.
The health utility scores of the AQOL before intervention
(baseline) and 12 months following completion of interven-
tion showed a mean (SD) gain in QALYs from 0.74 (0.22)
to 0.88 (0.17) in the exercise group and from 0.74 (0.17)
to 0.89 (0.11) in the control group. While there was a
significant gain in QALYs over 12 months within both
groups (both p < 0.001), the mean difference of 0.004 (95%
CI −0.08 to 0.09) between groups was not significant.
Discussion
To date, this is the only trial of exercise training and
regular review of ACT in non-CF bronchiectasis which
incorporated 12 months follow up. We have demon-
strated short term gains in exercise capacity as well asimprovement in symptoms of dyspnoea and fatigue, but
these benefits were not sustained beyond program
completion. With exercise training, the time to first ex-
acerbation was longer and the number of exacerbations
over a 12 month period was reduced. There was no bene-
fit in cough related QOL, change in levels of anxiety or
depression or greater improvement in QALYs.
This is the first study to show a reduction in the num-
ber of acute exacerbations over the 12 months following
exercise training and a longer time to first exacerbation.
While the reduced exacerbation frequency in the exercise
training group should be interpreted with caution, due
to the proportion of participants who were unable to
complete 12 months follow up, these findings are encour-
aging and are similar to case series reports [39]. The
mechanism by which exercise training reduced exacer-
bation frequency is unclear. It could be argued that the
review of ACT as necessary in the intervention group
may account for the difference, but the familiarity of all
participants with ACT prior to study enrolment, the lack
of change in ACT regimen for the intervention group and
the absence of reinforcement over the follow up suggests
Table 2 Effect of exercise training on cough related quality of life and psychological symptoms
Baseline 9 weeks 6 months 12 months p value
LCQ Physical
Exercise 5.0 (1.0) 5.3 (0.9) 4.7 (1.4) 4.8 (1.7)
Control 5.0 (1.0) 5.2 (0.8) 4.8 (1.6) 5.5 (1.1) 0.33
LCQ Psychological
Exercise 4.9 (1.8) 5.5 (1.3) 5.2 (1.7) 5.6 (1.2)
Control 5.7 (1.3) 5.8 (1.1) 5.3 (1.8) 6.2 (1.0) 0.11
LCQ Social
Exercise 5.3 (2.7) 4.6 (1.0) 5.5 (2.2) 3.1 (2.5) 0.98
Control 4.8 (1.1) 4.5 (0.9) 5.3 (1.9) 6.2 (1.2)
LCQ Total
Exercise 15.2 (3.4) 15.4 (2.1) 15.4 (1.6) 13.5 (3.1)
Control 15.5 (1.2) 15.5 (1.9) 15.4 (3.6) 17.9 (2.8) 0.82
HADS Anxiety
Exercise 4.8 (3.4) 4.6 (3.7) 3.7 (2.9) 3.1 (2.5)
Control 4.4 (3.1) 4.0 (2.7) 3.7 (3.2) 3.4 (3.5) 0.19
HADS Depression
Exercise 3.1 (2.9) 3.5 (3.4) 2.7 (2.7) 2.7 (2.7)
Control 3.5 (2.8) 3.2 (2.2) 3.5 (3.3) 2.9 (3.1) 0.63
Data are mean (SD), p value represents difference between groups.
LCQ – Leicester cough questionnaire; HADS – Hospital anxiety and depression scale.
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demonstrated with moderate intensity exercise in healthy
elderly individuals [40]; a similar mechanism may be
present in this study. In CF, the increase in expiratory flow
and promotion of annular airflow during a single session
of exercise has been associated with improved mucociliary
clearance, although the long term effects are unknown
[41]. We did not collect information related to bacterial
colonisation, or other markers in inflammation in this
study. Given the significant influence of distal airway col-
onisation upon exacerbation severity and decline inFigure 4 Time to first exacerbation, p = 0.047.lung function [7,42,43], further examination of the physio-
logical effects of exercise training is needed.
The mean improvement of 64 m in the ISWD and
41 m in the 6WMD is consistent with retrospective find-
ings in this patient population [15,16] as well as those
from a comprehensive pulmonary rehabilitation program
complemented by ACT [18]. Although the magnitude of
increase in ISWD was less in comparison to pulmonary
rehabilitation with inspiratory muscle training [17], it sug-
gests that exercise capacity improvement in bronchiectasis
can be achieved using training principles similar to those
applied in COPD [14,26]. While the level of functional
impairment prior to intervention was mild compared to
some studies [16,18], the MMRC grades and baseline
walking tests were equivalent to other reports of patients
included in pulmonary rehabilitation programs [17]. With






Exacerbations 2 (1 – 3) 1 (0 – 2) 0.012
Exacerbations requiring antibiotics 2 (0 – 4) 1 (0 – 2) 0.061
Exacerbation days 10 (2 – 13) 7 (3 – 11) 0.23
Exacerbation days with antibiotics 11 (2 – 15) 7 (2 – 13) 0.36
Data are median (IQR), p value represents difference between groups.
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those with more severe disease and impairment could
achieve even greater benefit from this intervention, but
this requires further investigation. Our results suggest
that the benefits appear to be independent of a com-
prehensive education program, which has been part of
previous work [15,17,18]. While the extent of improve-
ment in 6MWD is similar to the described minimal im-
portant difference in COPD [44], this has not yet been
defined for bronchiectasis. Therefore the clinical signifi-
cance of the improvements in exercise capacity requires
confirmation.
While exercise training was not associated with a greater
improvement in QALYs, in contrast to previous reports in
COPD [19], the study was not powered for this outcome
and the follow up time was short. Health utility is only
one dimension of the cost effectiveness and cost utility
of this treatment approach. Further exploration of the
economic benefit of this intervention, including measures
of cost per QALY [19,35] in bronchiectasis is warranted.
The short-term duration of benefit following exercise
training is a common finding in chronic respiratory con-
ditions [14]. Despite monthly telephone follow up and
instructions to complete an exercise diary beyond the
intervention period, the adherence rate was poor and
the absence of a structured exercise program may have
impeded the ability to maintain initial improvements.
While these results contrast with a retrospective report
of pulmonary rehabilitation, which demonstrated that
improvement was maintained at 12 months, these effects
may have been overestimated, with a significant attrition
rate (>50%) in this previous study [15]. The functional
decline over time reflects a similar pattern to that observed
in COPD and ILD [14,28], despite reports of a slower rate
of decline in lung function in bronchiectasis compared to
these conditions [45-48]. We found that the 6MWD at
12 months was worse than baseline, suggesting that despite
the mild disease evident in this sample, exercise capacity
has the potential to decline further over time. Reports
in COPD have demonstrated that immediately following
pulmonary rehabilitation, an increase in physical activity is
evident, but the magnitude is small, with suggestions that
a longer duration of treatment is necessary to encourage
behavioural change [49-51]. Our results suggest that sus-
tained gains in symptoms and functional capacity may
require longer interventions or maintenance programs
for people with bronchiectasis.
This is the first prospective study to isolate improve-
ment in dypsnoea and fatigue in people with non-CF
bronchiectasis, both key symptoms which contribute to
HRQOL [2,3]. The lack of change in psychological symp-
toms may be due to the few participants with clinically
significant anxiety or depression at baseline. Similarly, the
well preserved emotional function and mastery at studycommencement in both groups, a contrast to COPD [14],
may account for the lack of effect on these measures
following exercise training. Finally, all participants had
long-standing bronchiectasis and the possibility of a
greater tolerance of cough-related symptoms, as reflected
by the high baseline scores for the LCQ. These clinical
factors combined with similar initial instruction in ACT
and the consistent regimen during the study in both
groups may account for the negligible effect of exercise
training on cough-related QOL.
In conclusion, this study demonstrates that a supervised
exercise program of eight weeks is associated with short-
term improvement in exercise capacity, dyspnoea and
fatigue. Exercise training is associated with a reduction
in the frequency of acute exacerbations of bronchiectasis
over 12 months, however it appears to have minimal effect
on cough related QOL. The significance of these findings
for long-term prognosis requires further exploration.
Abbreviations
ACT: Airway clearance techniques; AQOL: Assessment of quality of life;
CF: Cystic fibrosis; COPD: Chronic obstructive pulmonary disease;
CRDQ: Chronic respiratory disease questionnaire; FEV1: Forced expiratory
volume in one second; FVC: Forced vital capacity; HADS: Hospital anxiety
and depression scale; HRQOL: Health-related quality of life; HRCT: High
resolution computed tomography; ILD: Interstitial lung disease;
IQR: Interquartile range; ISWD: Incremental shuttle walk distance;
ISWT: Incremental shuttle walk test; LCQ: Leicester cough questionnaire;
LOCF: Last observation carried forward; MMRC: Modified Medical Research
Council; QOL: Quality of life; SD: Standard deviation; VAS: Visual analogue
scale; 6MWD: 6-minute walk distance; 6MWT: 6-minute walk test.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design: AL, CH, NC, SJ, CM, LR, PT, RS, AH. Acquisition of
data: AL, CH, NC, SJ, AB. Analysis and interpretation: AL, CH, NC, SJ, CM, AH.
Drafting the article for important intellectual content: AL, CH, NC, SJ, CM, AB,
LR, PT, RS, AH. All authors contributed to the intellectual content of the
manuscript and were consulted for final approval of the submitted version.
Acknowledgements
This research was supported by The Alfred Foundation Research Trust, The
Institute for Breathing and Sleep, the Sir Charles Gairdner Hospital Research
Fund and the Alfred Physiotherapy Research Grant. The authors would like
to acknowledge Caroline Nicolson for her assistance in data management,
Holly Landers (blinded assessor), Nicole Stodden, intervention physiotherapist
and Leona Dowman, exercise physiologist.
Author details
1Alfred Health, Commercial Road, Melbourne 3004, Victoria, Australia.
2Institute for Breathing and Sleep, 145 Studley Road, Heidelberg 3084, Australia.
3Physiotherapy, Melbourne School of Health Sciences, The University of
Melbourne, 161 Barry Street, Carlton 3010, Australia. 4Austin Health, 145 Studley
Road, Heidelberg 3084, Australia. 5Sir Charles Gairdner Hospital, Hospital
Avenue, Nedlands, Perth 6009, Australia. 6Lung Institute of Western Australia
and Centre for Asthma, Hospital Avenue, Nedlands, Perth 6009, Australia.
7Curtin University, Kent Street, Bentley, Perth 6102, Australia. 8Department of
Medicine, Monash University, Melbourne 3800, Australia. 9Physiotherapy, La
Trobe University, Melbourne 3086, Australia.
Received: 24 January 2014 Accepted: 1 April 2014
Published: 15 April 2014
Lee et al. Respiratory Research 2014, 15:44 Page 9 of 10
http://respiratory-research.com/content/15/1/44References
1. Barker A: Bronchiectasis. N Engl J Med 2002, 346:1383–1393.
2. King P, Holdsworth SR, Freezer N, Villanueva E, Holmes PW:
Characteristation of the onset and presenting clinical features of adult
bronchiectasis. Respir Med 2006, 100:2183–2189.
3. Martinez Garcia M, Perpina Tordera M, Roman Sanchez P, Soler Cataluna JJ:
Quality of life determinants in patients with clinically stable
bronchiectasis. Chest 2005, 128:739–745.
4. Olveira C, Olveira G, Gaspar I, Dorado A, Cruz I, Soriguer F, Quittner AL,
Espildora F: Depression and anxiety symptoms in bronchiectasis: associations
with health-related quality of life. Qual Life Res 2013, 22:597–605.
5. Chang A, Bilton D: Exacerbation in cystic fibrosis: 4-Non cystic fibrosis
bronchiectasis. Thorax 2008, 63:269–276.
6. Finklea J, Khan G, Thomas S, Song J, Myers D, Arroliga AC: Predictors of
mortality in hospitalised patients with acute exacerbation of
bronchiectasis. Respir Med 2010, 104:816–821.
7. Martinez-Garcia M, Soler-Cataluna J, Perpina-Tordera M, Roman-Sanchez P,
Soriano J: Factors associated with lung function decline in adult patients
with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132:1565–1572.
8. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots R: Trends in
bronchiectasis among medicare beneficiaries in the United States, 2000
to 2007. Chest 2012, 142:432–439.
9. Seitz AE, Olivier KN, Steiner CA, Montes De Oca R, Holland SM, Prevots DR:
Trends and burden of bronchiectasis-associated hospitalizations in the
United States, 1993–2006. Chest 2010, 138:944–949.
10. Australian Institute of Health and Welfare: Asthma, chronic obstructive
pulmonary disease and other respiratory diseases in Australia, 2010.
[http://www.health.gov.au/internet/main/publishing.nsf/content/health-
pubhlth-strateg-phys-act-guidelines]
11. Joish V, Spilsbury-Cantalupo M, Operschall E, Luong B, Boklage S: Economic
burden of non-cystic fibrosis bronchiectasis in the first year after diagno-
sis from a US health plan perspective. Appl Health Econ Health Policy 2013,
11:299–304.
12. Ringshausen FC, de Roux A, Pletz MW, Hamalainen N, Welte J, Rademacher
J: Bronchiectasis-associated hospitalisation in Germany, 2005–2011 - a
population-based study of disease burden and trends. PLoS One 2013,
8:e71109.
13. Pasteur M, Bilton D, Hill A, Stockley RA, Wilson R, Pasteur MC, Herriot R,
Hansel DM, Bush A, Cornford C, Willcox L, Bilton D, Parry GW, Sonnappa S,
Wallis C, French J, Sinfield F, Harvey A, Bott J, Pryor J, Hill AT, Greenstone M,
Cunningham S, Spencer DA, Emmanue X, Kalima P, Heslop K, Elborn S, Carr
S, Cole B: British Thoracic Society guidelines for non-CF bronchiectasis.
Thorax 2010, 65:i1–i58.
14. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K,
Holland A, Lareau SC, Man MD, Pitta F, Sewell L, Raskin J, Bourbeau J,
Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R,
Clini EM, Effing TW, Maltais F, Van Der Palen J, Troosters T, Janssen DJ,
Collins E, Garcia Aymerich J, Brooks D, Fahy BF, et al: An official American
thoracic society/European respiratory society statement: key concepts
and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013,
188:e13–e64.
15. Ong H, Lee A, Hill C, Holland AE, Denehy L: Effects of pulmonary rehabilitation
in bronchiectasis: a retrospective study. Chron Respir Dis 2011, 8:21–30.
16. Zan Zellar M, Caetano P, Amorim A, Viana P, Martins P, Gaspar L, Hespanhol V,
Gomes I: Pulmonary rehabilitation in patients with bronchiectasis:
pulmonary function, arterial blood gases and the 6-minute walk test.
J Cardiopulm Rehabil Prev 2012, 32:278–283.
17. Newall C, Stockley R, Hill S: Exercise training and inspiratory muscle
training in patients with bronchiectasis. Thorax 2005, 60:943–948.
18. Mandal P, Sidhu M, Kope L, Pollock W, Stevenson LM, Pentland JL, Turnbull
K, MacQuarrie S, Hill AT: A pilot study of pulmonary rehabilitation and
chest physiotherapy versus chest physiotherapy alone in bronchiectasis.
Respir Med 2012, 106:1647–1654.
19. Griffiths T, Phillips C, Davies S, Davies S, Burr ML, Campbell IA: Cost
effectiveness of an outpatient multidisciplinary pulmonary rehabilitation
program. Thorax 2001, 56:779–784.
20. Lee A, Cecins N, Hill C, Holland AE, Rautela L, Stirling RG, Thompson P,
McDonald CF, Jenkins S: The effects of pulmonary rehabilitation in patients
with non-cystic fibrosis bronchiectasis: protocol for a randomised
controlled trial. BMC Pulm Med 2010, 10:1–7.21. Mahler D, Wells C: Evaluation of clinical methods for rating dyspnea.
Chest 1998, 93:580–586.
22. Global initative for chronic obstructive lung disease: Global strategy for
the diagnosis, management and prevention of chronic obstructive
pulmonary disease. 2013 [http://www.goldcopd.com/]
23. Global Initiative for Asthma (GINA): Global Strategy for Asthma
Management and Prevention. 2012 [http://www.ginasthma.org/]
24. Pryor JA, Prasad SA: Physiotherapy problems. In Physiotherapy for Respiratory
and Cardiac problems. Edited by Pryor JA, Prasad S. United Kingdom: Elsevier;
2008:398–394.
25. Alison J, Barrack C, Cafarella P, Frith P, Hanna C, Hill CJ, Holland AE, Jenkins S,
Meinhardt J, McDonald CF, McKeough Z, Patman S, Ross J, Seale H, Shoemaker
C, Spencer L, Allan H, Banks S, Barrett S, Beeley H, Blake J, Boden I, Cecins N,
Cockram J, Herd K, Hill K, Langdon C, Lee AL, Leung R, McNamara R, et al:
Pulmonary rehabilitation toolkit. [www.pulmonaryrehab.com.au]
26. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone
M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S,
MacIntye N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J,
Rochester C, Schols A, Singh S, Troosters T, on behalf of the ATS/ERS
Pulmonary rehabilitation writing committee: American Thoracic Society/
European Respiratory Society statement on pulmonary rehabilitation.
Am J Respir Crit Care Med 2006, 173:1390–1413.
27. Hill K, Jenkins SC, Cecins N, Philippe DL, Hillman DR, Eastwood PR: Estimating
maximal work rate during incremental cycle ergometry testing from
six-minute walk distance in patients with chronic obstructive pulmonary
disease. Arch Phys Med Rehabil 2008, 89:1782–1787.
28. Holland A, Hill C, Conron M, Munro P, McDonald CF: Short term
improvement in exercise capacity and symptoms following exercise
training in interstitial lung disease. Thorax 2008, 63:549–554.
29. Australian Government, Department of Health: Physical Activity guidelines.
2013 [http://www.health.gov.au/internet/main/publishing.nsf/content/
health-pubhlth-strateg-phys-act-guidelines#guidelines_adults]
30. Singh S, Morgan M, Scott S, Walters D, Hardman AE: Development of a
shuttle walking test of disability in patients with chronic airway
obstruction. Thorax 1992, 47:1019–1024.
31. Williams J, Singh S, Sewell L, Guyatt GH, Morgan MD: Development of a self-
reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax 2001, 56:954–959.
32. American Thoracic Society: Guidelines for the 6-minute walk test. Am J
Respir Crit Care Med 2002, 166:111–117.
33. Murray M, Turnbull K, MacQuarrie S, Pentland JL, Hill AT: Validation of the
Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur
Respir J 2009, 34:125–131.
34. Zigmond A, Snaith R: The hospital anxiety and depression scale. Acta
Pyschiatr Scand 1983, 67:361–370.
35. Hawthorn G, Osborne R: Population norms and meaningful differences
for the Assessment of Quality of Life (AQOL) measures. Aust NZ J Public
Health 2005, 29:136–142.
36. Lachin JM: Statistical considerations in the intent-to-treat principle.
Control Clin Trials 2000, 21:167–189.
37. Miller ME, Morgan TM, Espeland MA, Emerson SS: Group comparisons
involving missing data in clinical trials: a comparison of estimates and
power (size) for some simple approaches. Stat Med 2001, 20:2383–2397.
38. Schultz KF, Altman DG, Moher D, the CONSORT Group: CONSORT 2010
Statement: updated guidelines for reporting parallel group randomised
trials. BMC Med 2010, 8:18.
39. Santamato A, Ranieri M, Panza F, Frisardi V, Marvulli R, Filoni S, Cisari C, Fiore
P: Pulmonary rehabilitation for patients with bronchiectasis: case reports.
Eur J Phys Rehabil Med 2012, 48:293–298.
40. Akimoto T, Kumai Y, Hayashi E, Hayashi E, Murakami H, Soma R, Kuno S,
Kono I: Effects of 12 months of exercise training on salivary secretory IgA
levels in elderly subjects. Brit J Sports Med 2003, 37:76–79.
41. Dwyer T, Alison J, McKeough ZJ, Daviskas E, Bye PT: Effects of exercise on
respiratory flow and sputum properties in patients with cystic fibrosis.
Chest 2011, 139:870–877.
42. Angrill J, Agusti C, de Celis R, Rano A, Gonzalez J, Sole T, Xaubet A,
Rodriguez-Roison R, Torres A: Bacterial colonisation in patients with bron-
chiectasis: microbiological pattern and risk factors. Thorax 2002, 57:15–19.
43. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M,
Wilson R: Mortality in bronchiectasis: a long-term study assessing the factors
influencing survival. Eur Respir J 2009, 34:843–849.
Lee et al. Respiratory Research 2014, 15:44 Page 10 of 10
http://respiratory-research.com/content/15/1/4444. Puhan M, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, Wise RA,
Sciurba F: The minimal important difference of exercise tests in severe
COPD. Eur Respir J 2011, 37:784–790.
45. King PT, Holdsworth SR, Freezer NJ, Vallanueva E, Farmer MW, Guy P,
Holmes PW: Lung diffusing capacity in adult bronchiectasis: a
longitudinal study. Respir Care 2010, 55:1686–1692.
46. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Gallaher M, Holmes PW:
Outcome in adult bronchiectasis. Int J of Chron Obstruct Pulmon Dis 2005,
2:27–34.
47. Tantucci C, Modina D: Lung function decline in COPD. Int J of Chron
Obstruct Pulmon Dis 2012, 7:95–99.
48. Ley B, Collard HR, King TE Jr: Clinical course and prediction of survival in
idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 2011, 183:431–440.
49. Beauchamp M, Janaudis-Ferreira T, Goldstein R, Brooks D: Optimal duration
of pulmonary rehabilitation for individuals with COPD - a systematic
review. Chron Respir Dis 2011, 8:129–140.
50. Pitta F, Troosters T, Probst V, Langer D, Decramer M, Gosselink R: Are
patients with COPD more active after PR. Chest 2008, 134:273–280.
51. Wempe J, Wijkstra P: The influence of rehabilitation on behaviour
modification in COPD. Patient Educ Couns 2004, 52:237–241.
doi:10.1186/1465-9921-15-44
Cite this article as: Lee et al.: The short and long term effects of exercise
training in non-cystic fibrosis bronchiectasis – a randomised controlled trial.
Respiratory Research 2014 15:44.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
